Cargando…
Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil
BACKGROUND: P.1 lineage (Gamma) was first described in the State of Amazonas, northern Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of SARS-CoV-2 worldwide. P.1 has been linked to increased infectivity, higher mortality, and immune evasion, leading to rein...
Autores principales: | Zimerman, Ricardo Ariel, Ferrareze, Patrícia Aline Gröhs, Cadegiani, Flavio Adsuara, Wambier, Carlos Gustavo, Fonseca, Daniel do Nascimento, de Souza, Andrea Roberto, Goren, Andy, Rotta, Liane Nanci, Ren, Zhihua, Thompson, Claudia Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885995/ https://www.ncbi.nlm.nih.gov/pubmed/35242782 http://dx.doi.org/10.3389/fmed.2022.806611 |
Ejemplares similares
-
Predominance of the SARS-CoV-2 Lineage P.1 and Its Sublineage P.1.2 in Patients from the Metropolitan Region of Porto Alegre, Southern Brazil in March 2021
por: Franceschi, Vinícius Bonetti, et al.
Publicado: (2021) -
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
por: Cadegiani, Flavio A., et al.
Publicado: (2020) -
Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
por: Cadegiani, Flavio A., et al.
Publicado: (2020) -
SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study
por: Nguyen, Cristina, et al.
Publicado: (2021) -
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
por: McCoy, John, et al.
Publicado: (2021)